Healthcare
PE-owned Japanese drug maker seeks bankruptcy protection
Kyowa Pharmaceutical Industry, a Japanese generic drug manufacturer owned by Unison Capital, has applied for alternative dispute resolution, an out-of-court process that allows companies to continue operations while negotiating with creditors on a restructuring.
PE-backed Adlai Nortye pursues US listing
Adlai Nortye, a private equity-backed Chinese cancer drug developer that previously filed to list in Hong Kong, is now targeting an IPO in the US.
Deal focus: Topolefin finds favour as import substitution play
China-based Topolefin has gained traction thanks to breakthroughs in polymer science and the willingness of local medical equipment makers to use its components in foreign-dominated supply chains
Longreach sells Hong Kong medical devices player to Boyu
The Longreach Group has sold Quasar Medical, a Hong Kong-headquartered medical devices manufacturer it has owned since 2019, to Boyu Capital for an undisclosed sum.
Singapore's Mirxes raises $50m, files for Hong Kong IPO
Singapore-based biotech player Mirxes has raised USD 50m in Series D funding - at a post-money valuation of USD 600m - from the likes of Beijing-based Fupu Capital and Japan's Mitsui & Co, and filed to list in Hong Kong.
Astra leads Series D for Indonesia health-tech player Halodoc
Indonesia-based healthcare technology platform Halodoc has completed its Series D round with USD 100m in commitments. It comes more than two years after the company raised USD 80m in Series C funding.
Hong Kong's Immuno Cure raises $27m
Hong Kong’s Immuno Cure BioTech, a vaccine and antibodies developer focused on cancers, inflammatory and infectious diseases, has raised USD 27m in Series A funding featuring Gobi Partners.
BPEA EQT buys India fertility clinic business
BPEA EQT has agreed to acquire a controlling stake in Indira IVF, India’s largest fertility clinic chain, facilitating an exit for minority investor TA Associates.
China’s VectorBuilder becomes unicorn, files for Shanghai IPO
China-based gene delivery technology player VectorBuilder has topped up its Series C round - achieving unicorn status in the process - and filed for an IPO on Shanghai’s Star Market.
Mirae Asset PE arm seeks $200m for Fund II
Maps Capital, a private equity investment arm of Mirae Asset Financial Group, has launched its second US dollar-denominated fund with a target of USD 200m.
Hahn acquires Korea medical devices player
Hahn & Company has acquired a nearly two-thirds stake in Korea-listed medical laser maker Lutronic through a tender offer for about KRW 629bn (USD 497m).
China’s Cornerstone Robotics raises $112m
China-based Cornerstone Robotics, a surgical robots specialist, has raised a CNY 800m (USD 112m) round featuring BridgeOne Capital and Lenovo Capital & Incubator Group.
Legend Capital leads Series A for China CDMO CoJourney
China and US-based contract development and manufacturing organisation (CDMO) CoJourney has raised a Series A of USD 30m led by Legend Capital.
Quadria to invest $155m in India eye hospital
Quadria Capital has invested USD 155m in Maxivision Eye Hospital, a chain of 42 eye hospitals and vision clinics across five states in southern and western India.
Quadria to exit Vietnam's FV Hospital via $381m trade sale
Quadria Capital is set to exit Vietnam’s FV Hospital after a strategic buyer agreed to a USD 381.4m acquisition touted as the largest ever healthcare transaction in Vietnam.
Portfolio: True North and Integrace
True North has spent five years transforming Integrace from a low-margin drug portfolio into a broader, better-performing platform with digital capabilities. The M&A story isn’t finished yet
SDIC leads $97m Series A for China's Pyrotech Therapeutics
China-based Pyrotech Therapeutics, which develops treatments for inflammation and tumours, has raised a Series A of CNY 700m (USD 97m) led by state-owned investor SDIC Venture Capital.
Healthcare specialist CBC adds managing director
Asia healthcare investor CBC Group has appointed Billy Cho, formerly CFO of listed Chinese drug developer Zai Lab, as a senior managing director for private equity.
PE-backed Lu Daopei Medical files for Hong Kong IPO
Lu Daopei Medical Group Holding, which runs a network of hospitals in China that specialise in the treatment of blood diseases, has filed for a Hong Kong IPO.
Carlyle-backed Adicon trades up after $52m Hong Kong IPO
Adicon Holdings, a China-based independent clinical laboratory (ICL) services provider backed by The Carlyle Group, gained 12% on debut following a HKD 408.9m (USD 52.2m) Hong Kong IPO.
Singapore T-cell therapist gets China government funding
Singaporean T-cell immunotherapy company Lion TCR has raised USD 40m in its second tranche of Series B funding. Guangzhou Industrial Investment and Capital Operation Holding Group led the round.
Proparco makes $35m LP commitment to Quadria healthcare fund – update
French development finance institution (DFI) Proparco has made a USD 35m fund commitment to Singapore’s Quadria Capital, a healthcare-focused GP active across South and Southeast Asia.
Australia's Wesfarmers buys VC-backed Instascripts for $91m
InstantScripts, an Australia-based telehealth business backed by listed VC firm Bailador Technology Investments, has agreed to be acquired by Wesfarmers for approximately AUD 135m (USD 91m).
India's Lok seeks $200m for Fund IV, gets AIIB support
Indian impact investor Lok Capital has secured USD 25m from Asian Infrastructure Investment Bank (AIIB) for its fourth private equity fund. The target is USD 200m.